May 24, 2022
NHIA sent a letter to HHS requesting that the agency make permanent Medicare payment for COVID-19 monoclonal antibodies (mABs). HHS’s vaccine program created coverage for home and suite-based infusions of COVID mABs, which is set to expire at the end of the year in which the public health emergency (PHE) is terminated. NHIA points out that access to home infusion for mABs for the treatment and prevention of hospitalization and death due to severe COVID-19 and is critical to maintaining preparedness for potential future variants. With no oral therapies approved for prophylaxis, mABs are the only source of preventive therapy for vulnerable patients who do not respond to vaccines, such as transplant patients, cancer patients, and the immunocompromised.
NHIA commented on CMS’s Information Collection Request (ICR) regarding the Medicare Transaction Facilitator (MTF) that will be used in facilitating negotiated prices under the Medicare Drug Price Negotiation program.
The National Home Infusion Association (NHIA) is pleased to announce that Greg LoPresti, CEO Upstate HomeCare has been named Chair of its Board of Directors. LoPresti will lead the trade association representing companies that provide medically necessary infusion therapies to patients in alternate sites, as well as companies that manufacture and supply infusion and specialty pharmacy products.
Last week concluded the 2025 National Home Infusion Association Annual Conference (NHIA 2025), which brings together 1,600 home and alternate site infusion professionals for four days of networking, education, and exhibits. This year’s event saw significant growth in individuals investing to attend the event and the expo featured 150 companies displaying the latest products and services supporting the industry.
